Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera
Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal trials. Fourteen cases of tuberculosis have since b...
Main Authors: | Sylvain Lescuyer, Marie-Pierre Ledoux, Simon Gravier, Shanti Natarajan-Amé, Céline Duval, Fréderic Maloisel, Laurent Mauvieux, Elise Toussaint, Luc-Matthieu Fornecker, Raoul Herbrecht |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | International Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971219300128 |
Similar Items
-
Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01) -
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
by: Sakiyama E, et al.
Published: (2020-04-01) -
Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
by: Naomi Fei, et al.
Published: (2017-01-01) -
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
by: Vaddi K, et al.
Published: (2016-05-01)